Business Standard

Dr Reddys Laboratories Ltd News

Pharma shares shine; Dr Reddy's, FDC, Glenmark, Suven trade at record highs

Shares of Wockhardt hit a multi-year high of Rs 943.20, zooming 65 per cent in past nine trading days.

Pharma shares shine; Dr Reddy's, FDC, Glenmark, Suven trade at record highs
Updated On : 03 Jul 2024 | 2:57 PM IST

Earnings boost for Dr Reddy's Lab post consumer healthcare acquisition

In India, DRL has an OTC portfolio in the hydration, cough-cold-allergy, and skin care categories

Earnings boost for Dr Reddy's Lab post consumer healthcare acquisition
Updated On : 27 Jun 2024 | 9:57 PM IST

Dr Reddy's shares zoom post Nicotinell acquisition; brokerages unimpressed

On Thursday, shares of the Dr Reddy's Laboratories zoomed up to 2.7 per cent at Rs 6,235.90 a piece on the BSE. The stock rose after the company on Wednesday acquired OTC brand Nicotinell

Dr Reddy's shares zoom post Nicotinell acquisition; brokerages unimpressed
Updated On : 27 Jun 2024 | 11:03 AM IST

Dr Reddy's Laboratories, Warburg Pincus, EQT frontrunners to buy BSV

Advent looking to exit 4 years after it picked up majority stake in biopharma firm

Dr Reddy's Laboratories, Warburg Pincus, EQT frontrunners to buy BSV
Updated On : 18 Jun 2024 | 9:16 PM IST

USFDA issues Form 483 with four observations to Dr Reddy's API unit

Dr Reddy's Laboratories on Friday said the US health regulator has issued Form 483 with four observations after inspecting its Andhra Pradesh-based API manufacturing facility. The US Food & Drug Administration (USFDA) today completed a GMP inspection at the company's API manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh, the Hyderabad-based drug major said in a regulatory filing. The inspection was conducted from May 30, 2024 to June 7, 2024, it added. "We have been issued a Form 483 with four observations, which we will address within the stipulated timeline," the drug firm said. As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

USFDA issues Form 483 with four observations to Dr Reddy's API unit
Updated On : 07 Jun 2024 | 11:24 PM IST

Dr Reddy's Laboratories eyes acquisitions to drive growth in India

The share of chronic has been steadily rising in the Rs 2 lakh crore domestic pharma market- from 36.4 percent in January 2022 to 38.1 percent in January 2024

Dr Reddy's Laboratories eyes acquisitions to drive growth in India
Updated On : 07 Jun 2024 | 8:47 PM IST

Sun Pharma, Dr Reddy's pull drugs in US over manufacturing issues: USFDA

Sun Pharma and Dr Reddy's Laboratories are recalling products in the American market due to manufacturing issues, the US Food and Drug Administration (USFDA) has said. In its latest Enforcement Report, the US health regulator stated that a US-based unit of Sun Pharma is recalling 35,069 bottles of medication used to treat high pressure inside the eye due to glaucoma or other eye diseases. New Jersey-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Xelpros (latanoprost ophthalmic emulsion) due to "out of specification for particulate matter test". The company initiated the voluntary Class III recall in the US on April 22 this year, the USFDA stated. In a separate filing, the USFDA stated that a US-based arm of Dr Reddy's Laboratories is recalling 1,176 bottles of an immunosuppressant medication. Dr Reddy's Laboratories Inc is recalling the affected lot of Sirolimus Tablets due to "Failed Impurities/Degradation Specifications", the USFDA said. The company ...

Sun Pharma, Dr Reddy's pull drugs in US over manufacturing issues: USFDA
Updated On : 30 May 2024 | 7:44 PM IST

Drug makers Dr Reddy's, Sun Pharma, Aurobindo recall products in US market

Drug makers Dr Reddy's Laboratories, Sun Pharma and Aurobindo Pharma are recalling products in the US market due to manufacturing issues, as per the latest Enforcement Report of the US Food and Drug Administration (USFDA). Dr Reddy's Laboratories is recalling close to 20,000 cartons of a medication used to control blood phenylalanine levels in adults and children. Princeton (New Jersey) based Dr Reddy's Laboratories, Inc, is recalling Javygtor (sapropterin dihydrochloride) Powder for Oral Solution (100mg) due to it being a "Sub-potent Drug", USFDA stated. The company is also recalling another lot of sapropterin dihydrochloride for the same reason, it added. The USFDA said the drug maker initiated the Class I recall in the US on April 8 this year. As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems. The USFDA said Sun Pharma is recalling 11,016 vials of Amphotericin B Liposome for Injection, used to treat fungal ...

Drug makers Dr Reddy's, Sun Pharma, Aurobindo recall products in US market
Updated On : 19 May 2024 | 11:35 AM IST

Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings

The miss was driven by lower Revlimid sales, muted growth across markets and higher R&D spends. While the prevailing US tailwinds provide stability, absence of any meaningful approvals for Dr Reddy's

Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings
Updated On : 08 May 2024 | 10:30 AM IST

Dr Reddy's Labs Q4 profit jumps 36% led by US growth, new products

During the quarter, the company launched 5 new products, of which 4 were launched in the US. A total of 21 products were launched during the year

Dr Reddy's Labs Q4 profit jumps 36% led by US growth, new products
Updated On : 07 May 2024 | 9:41 PM IST

Dr Reddy's Q4 results: Net profit rises 36% to Rs 1,307 cr, revenue up 12%

Q4FY24 results: The company board has recommended a final dividend of Rs 40 per equity share of Rs 5 each for the financial year 2023-24

Dr Reddy's Q4 results: Net profit rises 36% to Rs 1,307 cr, revenue up 12%
Updated On : 07 May 2024 | 4:33 PM IST

Nifty pre-market news: All you need to know before stocks open on May 7

Indian stock market update on Tuesday, May 07: Global cues, Gift Nifty hint at gap-up start; Q4 earnings, FII flows in focus.

Nifty pre-market news: All you need to know before stocks open on May 7
Updated On : 07 May 2024 | 7:17 AM IST

Dr Reddy's Q4 Preview: Here's what key brokerages expect from its results

Indian pharmaceutical giant Dr Reddy's Laboratories is set to witness a single to double digit growth in sales on a year-on-year (Y-o-Y) basis for the fourth quarter of financial year 2023-24 (Q4FY23)

Dr Reddy's Q4 Preview: Here's what key brokerages expect from its results
Updated On : 06 May 2024 | 12:20 PM IST

Anand Rathi recommends buy on Dr.Reddys, Cipla and Piramal Enterprises

Stock picks by Anand Rathi: DR Reddy shows a strong uptrend with higher highs and higher lows on a weekly scale

Anand Rathi recommends buy on Dr.Reddys, Cipla and Piramal Enterprises
Updated On : 06 May 2024 | 7:43 AM IST

Dr Reddy's Laboratories launches generic anti-bacterial medication in US

Dr Reddy's Laboratories on Friday said it has launched a generic medication, used to treat a wide variety of bacterial infections, in the US market. The company has launched Doxycycline Capsules (40 mg) in the US market, the Hyderabad-based drug maker said in a statement. The company's product is a therapeutic generic equivalent of Oracea capsules (40 mg) approved by the US Food and Drug Administration (USFDA). Shares of the company on Friday ended 0.71 per cent up at Rs 6,332.85 apiece on the BSE.

Dr Reddy's Laboratories launches generic anti-bacterial medication in US
Updated On : 03 May 2024 | 5:20 PM IST

Nestle India, Dr Reddy's to form JV for nutraceutical brands in India

Nestle India and Dr Reddy's Laboratories Ltd on Thursday announced that they have entered into a definitive agreement to form a joint venture to bring innovative nutraceutical brands to consumers in India and other agreed territories. A joint press release from the companies said the partnership will bring together the well-known global range of nutritional health solutions as well as vitamins, minerals, herbals and supplements of Nestle Health Science (NHSc) with the strong and established commercial strengths of Dr Reddy's in India. The move will help JV partners combine their strengths and grow their complementary nutraceuticals portfolios in categories such as metabolic, hospital nutrition, general wellness , women's health and child nutrition for consumers across India, it said. Select brands will be licensed by the respective companies to the JV company. The Nestl Group will licence brands such as Nature's Bounty, Osteo Bi-Flex, Ester-C, Resource High Protein, Optifast, Resour

Nestle India, Dr Reddy's to form JV for nutraceutical brands in India
Updated On : 25 Apr 2024 | 5:07 PM IST

Dr Reddy's, Bayer partner to market second brand of Vericiguat in India

Vericiguat is currently approved for use in 35 countries

Dr Reddy's, Bayer partner to market second brand of Vericiguat in India
Updated On : 05 Apr 2024 | 7:54 PM IST

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India
Updated On : 27 Mar 2024 | 4:45 PM IST

Dr Reddy's, Pharmazz ink licence pact to commercialise resuscitative agent

With this agreement, India will become the first global territory where Centhaquin (Lyfaquin) is being launched immediately, according to the company

Dr Reddy's, Pharmazz ink licence pact to commercialise resuscitative agent
Updated On : 22 Mar 2024 | 8:24 PM IST

Analysts favour defensive bets as hedge against equity market downturn

From defensives, Nifty Pharma index has led gains so far in calendar year 2024 with a surge of 11 per cent, followed by Nifty IT, which is up 4 per cent while Nifty FMCG has shed 6 per cent

Analysts favour defensive bets as hedge against equity market downturn
Updated On : 15 Mar 2024 | 10:20 AM IST